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Abstract 
 
Important oncological management decisions rely on kidney function assessed by serum 
creatinine-based estimated glomerular filtration rate (eGFR). However, no large-scale 
multicentre comparison of methods to determine eGFR in patients with cancer are available.  
To compare the performance of formulas for eGFR based on routine clinical parameters and 
serum creatinine not calibrated with isotope dilution mass spectrometry (non-IDMS), we 
studied 3,620 patients with cancer and 166 without cancer who had their GFR measured 
with an exogenous nuclear tracer at one of seven clinical centres. The mean measured GFR 
was 86 ml/min. Accuracy of all models was centre-dependent, reflecting inter-centre 
variability of non-IDMS creatinine measurements. CamGFR was the most accurate model 
for eGFR (root-mean-squared-error (RMSE) 17.3 ml/min) followed by the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) model (RMSE 18.2 ml/min). 
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Manuscript 
 
Knowledge of kidney function measured as the glomerular filtration rate (GFR) informs 
clinical practice.1 GFR can be accurately measured (mGFR) using exogenous nuclear tracer 
clearance, but in practice is frequently estimated (eGFR) using models based on routine 
clinical and biochemical data, specifically serum creatinine concentration. Creatinine is 
commonly measured using Jaffe or enzymatic methods which in turn are calibrated using an 
isotope dilution mass spectrometry (IDMS) standard or a non-IDMS standard.2  
 
Recently, we derived a new model for GFR (CamGFR) using data from patients with cancer 
treated at the Cambridge University Hospitals NHS Foundation Trust, United Kingdom.3 
CamGFR modelled GFR on a square root scale using non-IDMS creatinine and biometric 
patient data and estimated GFR more accurately than other published models. This gain 
increased accuracy in GFR-based carboplatin chemotherapy dose calculations.3 Here we 
validate these findings for non-IDMS creatinine-based estimation of GFR using multicentre 
data from patients with and without cancer.  
 
Data were from the University Hospitals NHS Foundation Trusts in Cambridge, 
Southampton4, and Manchester; Barts Health NHS Trust, London; a combined Welsh 
dataset5,6; Western General Hospital, Edinburgh; and the Peter MacCallum Cancer Institute, 
Melbourne7. Data on age, sex, height, weight, serum creatinine concentration, 
histopathologically confirmed cancer diagnosis, ethnicity, and mGFR were obtained. Either 
51Cr-EDTA or 99mTc-DTPA clearance were used to measure GFR.8,9 Serum creatinine was 
determined by enzymatic or Jaffe methods within 30 days of the mGFR date (Table S1). 
Adult patients with creatinine levels between 0.20 mg/dL and 4.5 mg/dL were included. From 
patients with multiple mGFR values, we only included the first value by date. Body surface 
area (BSA) was calculated using the DuBois & DuBois equation.10 The study was conducted 
at each institution according to its relevant regulatory and ethical requirments.  
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 We compared mGFR with eGFR provided by six published models (CamGFR3, Martin11, 
Wright12, Mayo13, Modification of Diet in Renal Disease (MDRD) version 18614, and CKD-
EPI15), along with two models for creatinine clearance (Cockcroft-Gault16 and Jelliffe17).  
 
To assessed model performance, statistics were determined for bias (residual median), 
precision (residual interquartile range (IQR)), and accuracy (root-mean-squared error 
(RMSE)) and clinical robustness, by calculating the proportion of patients with an absolute 
percentage error greater than 20% (1-P20) for eGFR. 95% confidence intervals (CI) and p-
values were approximated using bootstrap resampling.18 
 
Data from 3,786 patients were included; 3,484 patients had solid cancer, 136 had 
haematological cancer, and 166 had a non-cancer diagnosis (Table 1). Creatinine values 
and mGFR were obtained on the same day for 27% and within a week for 89% of patients 
(Figure S1). The median mGFR was 85 ml/min (IQR 61 to 109 ml/min). The median serum 
creatinine value was 0.95 mg/dL (IQR 0.83 to 1.11 mg/dL). The median age, height, weight 
and BSA were 60 years, 169 cm, 74 kg and 1.85 m2 respectively (Table 1). Centre-specific 
summary statistics are provided in the supplement (Figures S2-S4, Tables S2-S3).  
 
CamGFR was significantly more accurate in estimating GFR than all other models, both by 
RMSE or 1-P20, followed by the CKD-EPI model (Figure 1, Figure S6, Table S5). The 
RMSE for the CamGFR model was 17.3 ml/min (CI 16.7 to 17.9 ml/min) and 18.2 ml/min (CI 
17.6 to 18.7 ml/min) for the CKD-EPI model (p-value = 0.03) and the 1-P20 results for 
CamGFR was 0.295 (CI 0.280 to 0.309) and 0.318 (CI 0.303 to 0.333) for CKD-EPI, 
respectively (p-value = 0.03). In subgroup analyses CamGFR was the most accurate model 
for most patients subgroups divided by tumour type, age, BSA, serum creatinine, or sex 
(Figures S7-S10) 
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 Finally, CamGFR had the lowest RMSE for both male and female patients and in six out of 
seven centres. Model performance was not consistent between centres (Table S5, Figure 1), 
probably reflecting differences in non-IDMS creatinine values (Figure S3). 
 
We did not adjust the CamGFR model to include race as a potential variable for two 
reasons, the small number of black patients (n=22) and the absence of a statistically 
significant difference in BSA, mGFR, or serum creatinine when we compared 10 random 
data draws matched for age and sex between non-black and black patients (Figure S5, 
Table S4). Other studies have documented systematic differences for the relationship 
between eGFR and creatinine for black patients14,15 and our study is probably underpowered 
to detect this. The use of non-IDMS creatinine data in this study represents a further 
limitation.20 Differences between non-IDMS and IDMS creatinine exist2 and future work 
should expand the CamGFR model to IDMS-creatinine data use. Of note, the CKD-EPI 
model was developed for use with IDMS-creatinine measurements specifically, but still 
outperformed other models that have been developed with non-IDMS data.  
 
The data were mostly from chemotherapy treatment naive patients with cancer and the 
longitudinal effect of treatment on eGFR requires further study. Probably attributable to the 
near-normal renal function of the majority of patients in our study, we find that the underlying 
diagnosis of the patients does not impact the suitability of the models significantly. CamGFR, 
developed on data from patients with cancer, performs best in non-cancer patients and 
CKD-EPI, developed on data from patients without cancer, performs well for data from 
patients with cancer.  
 
This work is based on data from seven centres and confirms that of the available models the 
CamGFR model estimates GFR most accurately, but the CKD-EPI model performs nearly as 
well overall and across the spectrum of relevant subgroups. The greatest gain in accuracy 
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by these newer models over the older models, such as Cockcroft-Gault and Wright, was 
observed in younger patients and patients with lower creatinine values, probably reflecting 
the differences in model development populations.  However, even considering the different 
patient populations in different centres, it is likely that errors in estimating GFR can be 
reduced by standardising the methods used to measure serum creatinine at different 
laboritories and use of appropriate models. Given the linear relationship between GFR and 
carboplatin dose via the Calvert equation21, improved estimates of GFR using CamGFR will 
translate into more accurate carboplatin prescriptions.  
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Centre Total Solid 
cancer 
Haematological 
cancer 
Non-
cancer 
Female Race - 
Black 
Cambridge     404 227 114 63 198 6 
Edinburgh     597 472 22 103 245 0 
London-Barts 108 108 0 0 0 0 
Manchester    1777 1777 0 0 1066 16 
Melbourne 308 308 0 0 111 0 
Southampton 436 436 0 0 0 0 
Wales 156 156 0 0 89 0 
Total 3786 3484 136 166 1709 22 
        
 Mean SD Minimum Q1 Median  Q3 Maximum 
GFR (ml/min)        86    32 9 61 85 109 209 
Creatinine (mg/dL) 0.99 0.28 0.43 0.83 0.95 1.11 4.45 
Age (years)       57 16 18 45 60 70 91 
Weight (kg)  76 19 33 63 74 87 200 
Height (cm) 169 11 137 160 169 177 204 
BSA (m2)            1.85 0.25 1.17 1.68 1.85 2.02 3.17 
   
Table 1: Characteristics of study patients. Summary of categorical data split by centre (top). 
Summary of continuous data for all patients (bottom). GFR was measured using either 
99mTc-DTPA (Edinbrugh and Melbourne) or 51Cr-EDTA (all others). GFR - Glomerular 
filtration rate, BSA - Body surface area (calculated using DuBois-DuBois), SD - Standard 
deviation , Q1 - 25th percentile, Q3 - 75th percentile  
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Figure 1: Performance analysis of commonly used and well performing models. Results for 
the five best-performing models (CamGFR, CKD-EPI, Wright, MDRD-186 and Cockcroft- 
Gault) for the 3,776 patients from the non-IDMS creatinine validation dataset are displayed. 
Performance analysis of the other models is included in Table S5. A pooled analysis of data 
from all centres and the individual centre analyses are shown. (first row) The residual 
(measured GFR - estimated GFR) median, which is a measure of a model’s bias, is 
displayed. (second row) The residual interquartile range (IQR), which is a measure of a 
model’s precision, is displayed. (third row) The root-mean-squared error (RMSE), which is a 
measure of a model’s accuracy, is displayed. Accuracy is a combination metric of bias and 
precision. (fourth row) The proportion of patients who have an absolute percentage error 
more than 20% (1-P20), which reflects clinical robustness by illustrating the proportion of 
patients with a clinically relevant error, is displayed.  
The best results are closest to zero for the residual median, and the smallest value for IQR, 
RMSE, and 1-P20. All error bars are 95% confidence intervals calculated using bootstrap 
resampling with 2,000 repetitions and a normal distribution approximation.  
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